Companies › Grifols Therapeutics
3 active drug programs in 4 registered trials: 4 Phase 3; Respiratory, Neurology, Oncology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Alpha-1 15% (DRUG): Alpha1-Proteinase Inhibitor Subcutaneous (Human), 15% Protease inhibitor replacement therapy - recombinant alpha-1 antitrypsin (AAT) replacement | SERPINA1 | Phase 3 | Alpha 1 Antitrypsin Deficiency | Sep 2027 |
| Xembify Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified | – | Phase 3 | CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy); Hypogammaglobulinemia | Dec 2027 |
| .Alpha.1-Proteinase Inhibitor Human Leukocyte elastase inhibitor | ELANE | Phase 3 | Pulmonary Emphysema in Alpha-1 PI Deficiency | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT01983241 | .Alpha.1-Proteinase Inhibitor Human | Phase 3 | Pulmonary Emphysema in Alpha-1 PI Deficiency | Respiratory | Jul 2026 |
| NCT07555483 | Alpha-1 15% (DRUG): Alpha1-Proteinase Inhibitor Subcutaneous (Human), 15% | Phase 3 | Alpha 1 Antitrypsin Deficiency | Respiratory | Sep 2027 |
| NCT07540221 | Xembify | Phase 3 | CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | Neurology | Dec 2027 |
| NCT05645107 | Xembify | Phase 3 | Hypogammaglobulinemia | Oncology | Aug 2029 |
Krystal Biotech Takeda Tessera Therapeutics Wave Life Sciences USA Beam Therapeutics Onchilles Pharma CSL Behring
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.